Literature DB >> 33155899

Cardiovascular Risk in Patients with Primary Hyperparathyroidism.

Symeon Tournis1, Konstantinos Makris2, Etienne Cavalier3, George Trovas1.   

Abstract

Primary hyperparathyroidism (PHPT) is one of the most common endocrine disorders characterized by parathyroid hormone (PTH)-dependent hypercalcemia. Cardinal features include low trauma fractures, nephrolithiasis, and chronic kidney disease. Several experimental studies established that parathyroid hormone exerts actions on the cardiovascular (CV) system, including vasodilatation and positive inotropic and chronotropic effects. Observational studies, especially in severe cases, report a higher prevalence of hypertension, diabetes mellitus, lipid abnormalities, endothelial dysfunction, arrhythmias, and left ventricular hypertrophy in patients with PHPT, while the risk of CV events seems to be increased in severe cases. However, the effect of surgery is inconsistent on CV abnormalities and, more importantly, on CV disease (CVD) events, especially in mild cases. In the current review, we describe the available evidence linking PHPT and CVD, as well as the effect of surgical management and pharmacological treatment on CVD manifestations in patients with PHPT. Based on the current evidence, CVD is not considered an indication for surgery. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Primary hyperparathyroidism; calcium; cardiovascular disease; hypertension; parathyroid hormone; parathyroidectomy

Year:  2020        PMID: 33155899     DOI: 10.2174/1381612824999201105165642

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Residual risks of comorbidities after parathyroidectomy in a nationwide cohort of patients with primary hyperparathyroidism.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  Endocrine       Date:  2022-10-12       Impact factor: 3.925

2.  Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study.

Authors:  Domenico Rendina; Lanfranco D Elia; Veronica Abate; Andrea Rebellato; Ilaria Buondonno; Mariangela Succoio; Fabio Martinelli; Riccardo Muscariello; Gianpaolo De Filippo; Patrizia D Amelio; Francesco Fallo; Pasquale Strazzullo; Raffaella Faraonio
Journal:  Nutrients       Date:  2022-06-28       Impact factor: 6.706

Review 3.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 4.  Arterial Stiffness in Thyroid and Parathyroid Disease: A Review of Clinical Studies.

Authors:  Andrea Grillo; Vincenzo Barbato; Roberta Maria Antonello; Marco Fabio Cola; Gianfranco Parati; Paolo Salvi; Bruno Fabris; Stella Bernardi
Journal:  J Clin Med       Date:  2022-06-01       Impact factor: 4.964

Review 5.  Diabetes and Bone Involvement in Primary Hyperparathyroidism: Literature Review and Our Personal Experience.

Authors:  Elena Castellano; Roberto Attanasio; Alberto Boriano; Valentina Borretta; Francesco Tassone; Giorgio Borretta
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-19       Impact factor: 5.555

6.  Response of Bone Metabolism Markers to Ice Swimming in Regular Practitioners.

Authors:  Shuai Mu; Yang Xia; Qijun Wu; Chao Ji; Huixu Dai; Ming Zhang; Jiao Jiao; Feng Shi; Shengye Liu; Guangbin Wang; Tao Shen; Ye Tian; Liqing Yang; Qin Fu; Yuhong Zhao
Journal:  Front Physiol       Date:  2021-11-26       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.